Evogene Ltd.
EVGNNASDAQHealthcare● Active
$0.58
$-0.04(-5.82%)
Market Cap$5023607
P/E Ratio—
52W High$2.42
52W Low$0.52
Evogene Ltd. (EVGN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EVGN · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 20, 2026EPS Actual
-$0.60
Est. -$0.27 · -122.2%
Revenue
$0.00B
Est. $0.00B · -4.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 20, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
EVGN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.52
Rev. $3.34B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.52
Rev. Est.$3.34B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 26, 2026 | -$0.27 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 20, 2026 | -$0.27 | -$0.60 | -122.2% | $0.00B | $0.00B | -4.6% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -$0.26 | -$0.61 | -134.6% | $0.00B | $0.00B | +14.2% |
| ▼ Q4 FY2025 | Nov 20, 2025 | -$0.26 | -$0.31 | -19.2% | $0.00B | $0.00B | +13.4% |
| — Q3 FY2025 | Aug 28, 2025 | — | -$1.06 | — | $0.00B | — | — |
| ▲ Q2 FY2025 | May 21, 2025 | -$0.63 | -$0.38 | +39.2% | $0.00B | $0.00B | +25.8% |
| ▲ Q1 FY2025 | Mar 6, 2025 | -$0.72 | $0.06 | +108.3% | $0.00B | $0.01B | -67.8% |
| ▼ Q4 FY2024 | Nov 21, 2024 | -$1.01 | -$1.31 | -29.7% | $0.00B | $0.00B | -52.0% |
Q3 FY2026
Aug 26, 2026
EPS Actual
—
EPS Est.
-$0.27
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 20, 2026Miss
EPS Actual
-$0.60
EPS Est.
-$0.27
EPS Surpr.
-122.2%
Revenue
$0.00B
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
-$0.61
EPS Est.
-$0.26
EPS Surpr.
-134.6%
Revenue
$0.00B
Q4 FY2025
Nov 20, 2025Miss
EPS Actual
-$0.31
EPS Est.
-$0.26
EPS Surpr.
-19.2%
Revenue
$0.00B
Q3 FY2025
Aug 28, 2025
EPS Actual
-$1.06
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
May 21, 2025Beat
EPS Actual
-$0.38
EPS Est.
-$0.63
EPS Surpr.
+39.2%
Revenue
$0.00B
Q1 FY2025
Mar 6, 2025Beat
EPS Actual
$0.06
EPS Est.
-$0.72
EPS Surpr.
+108.3%
Revenue
$0.00B
Q4 FY2024
Nov 21, 2024Miss
EPS Actual
-$1.31
EPS Est.
-$1.01
EPS Surpr.
-29.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q3 FY2026 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q2 FY2026 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q1 FY2026 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q4 FY2025 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q3 FY2025 | $-0.41 | $-0.41 | $-0.41 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 20, 2026 | -122.2% | $0.74 | $0.72 | -3.24% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -134.6% | $0.84 | $0.79 | -6.16% |
| ▼ Q4 FY2025 | Nov 20, 2025 | -19.2% | $1.17 | $1.08 | -7.69% |
| — Q3 FY2025 | Aug 28, 2025 | — | $1.31 | $1.29 | -1.53% |
| ▲ Q2 FY2025 | May 21, 2025 | +39.2% | $1.27 | $1.19 | -6.30% |
| ▲ Q1 FY2025 | Mar 6, 2025 | +108.3% | $1.41 | $1.41 | +0.00% |
| ▼ Q4 FY2024 | Nov 21, 2024 | -29.7% | $1.65 | $1.60 | -3.03% |
| ▼ Q3 FY2024 | Aug 22, 2024 | -783.3% | $3.98 | $3.55 | -10.80% |
Q2 FY2026-3.24%
Report Date
May 20, 2026
EPS Beat/Miss
-122.2%
Price Before
$0.74
Price After
$0.72
Q1 FY2026-6.16%
Report Date
Mar 5, 2026
EPS Beat/Miss
-134.6%
Price Before
$0.84
Price After
$0.79
Q4 FY2025-7.69%
Report Date
Nov 20, 2025
EPS Beat/Miss
-19.2%
Price Before
$1.17
Price After
$1.08
Q3 FY2025-1.53%
Report Date
Aug 28, 2025
EPS Beat/Miss
—
Price Before
$1.31
Price After
$1.29
Q2 FY2025-6.30%
Report Date
May 21, 2025
EPS Beat/Miss
+39.2%
Price Before
$1.27
Price After
$1.19
Q1 FY2025+0.00%
Report Date
Mar 6, 2025
EPS Beat/Miss
+108.3%
Price Before
$1.41
Price After
$1.41
Q4 FY2024-3.03%
Report Date
Nov 21, 2024
EPS Beat/Miss
-29.7%
Price Before
$1.65
Price After
$1.60
Q3 FY2024-10.80%
Report Date
Aug 22, 2024
EPS Beat/Miss
-783.3%
Price Before
$3.98
Price After
$3.55
Avg Beat Reaction-3.15%
Avg Miss Reaction-6.18%
Beat Rate2 / 8 quarters
Largest Move-10.80% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EVGN ends December
Evogene Ltd. (EVGN) most recently reported earnings on May 20, 2026 for Q2 FY2026, posting EPS of $-0.60 — missing the analyst consensus of $-0.27 by -122.2%. The next EVGN earnings date is expected around September 1, 2026.
Each quarter, investors track EVGN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EVGN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EVGN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EVGN earnings · 5 questionsEvogene Ltd.'s next earnings report is expected around September 1, 2026. EVGN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EVGN historically reports after market close (AMC).
EVGN earnings datewhen is EVGN earningsEVGN next earnings datewhen does EVGN report earningsEVGN earnings calendar
▸ Source: FMP · Evogene Ltd. SEC filings · US GAAP · Evogene Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026